Osteopontin Promotes Left Ventricular Diastolic Dysfunction Through a Mitochondrial Pathway.

[1]  J. Kovacic,et al.  Extracellular Matrix in Ischemic Heart Disease, Part 4/4: JACC Focus Seminar. , 2020, Journal of the American College of Cardiology.

[2]  Keyvan Yousefi,et al.  A preclinical model for phenogroup 3 HFpEF , 2019, Aging.

[3]  D. Kitzman,et al.  The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo‐controlled, double‐blind trial , 2018, American heart journal.

[4]  Claire Gerber,et al.  Genetic background influences cardiac phenotype in murine chronic kidney disease , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  A. Mendez,et al.  Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits. , 2018, JCI insight.

[6]  Keyvan Yousefi,et al.  Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure , 2017, Cardiovascular research.

[7]  R. D. de Boer,et al.  Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction , 2017, Journal of the American Heart Association.

[8]  Michael F. Wangler,et al.  Loss of Nardilysin, a Mitochondrial Co-chaperone for α-Ketoglutarate Dehydrogenase, Promotes mTORC1 Activation and Neurodegeneration , 2017, Neuron.

[9]  G. Filippatos,et al.  Mitochondrial function as a therapeutic target in heart failure , 2016, Nature Reviews Cardiology.

[10]  D. Kass,et al.  Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap , 2016, Circulation.

[11]  W. Paulus,et al.  Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation , 2016, European journal of heart failure.

[12]  W. Paulus,et al.  Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction. , 2016, JACC. Heart failure.

[13]  R. Wachter,et al.  Tolerability and Feasibility of Beta-Blocker Titration in HFpEF Versus HFrEF: Insights From the CIBIS-ELD Trial. , 2016, JACC. Heart failure.

[14]  Akshay S. Desai,et al.  Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. , 2016, European heart journal.

[15]  Sanjiv J. Shah,et al.  Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction , 2016, European journal of heart failure.

[16]  S. Solomon,et al.  Assessing Contractile Function When Ejection Fraction Is Normal: A Case for Strain Imaging. , 2015, Circulation. Cardiovascular imaging.

[17]  Downregulation of OGDHL expression is associated with promoter hypermethylation in colorectal cancer , 2015, Molecular Biology.

[18]  Peter Van Buren,et al.  Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction: Contributions of Collagen and Titin , 2015, Circulation.

[19]  U. Wisløff,et al.  Heart failure with preserved ejection fraction induces molecular, mitochondrial, histological, and functional alterations in rat respiratory and limb skeletal muscle , 2015, European journal of heart failure.

[20]  S. Solomon,et al.  Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. , 2014, European heart journal.

[21]  Shunichi Homma,et al.  Prevalence and prognostic value of subclinical left ventricular systolic dysfunction by global longitudinal strain in a community‐based cohort , 2014, European journal of heart failure.

[22]  M. Borggrefe,et al.  Diagnostic and prognostic value of osteopontin in patients with acute congestive heart failure , 2013, European journal of heart failure.

[23]  Robert J. Vincent,et al.  FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. , 2013, American journal of physiology. Endocrinology and metabolism.

[24]  L. Bettendorff,et al.  Up-regulation of 2-oxoglutarate dehydrogenase as a stress response. , 2013, The international journal of biochemistry & cell biology.

[25]  M. Hoque,et al.  OGDHL Is a Modifier of AKT-Dependent Signaling and NF-κB Function , 2012, PloS one.

[26]  Miranda D. Stobbe,et al.  Improving the description of metabolic networks: the TCA cycle as example , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  R. McKelvie,et al.  Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction: Results of the I-PRESERVE Collagen Substudy , 2011, Circulation. Heart failure.

[28]  R. McKelvie,et al.  Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction: Findings From the I-PRESERVE Trial , 2011, Circulation. Heart failure.

[29]  C. Nam,et al.  Usefulness of Tissue Doppler Imaging‐Myocardial Performance Index in the Evaluation of Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction , 2011, Clinical Cardiology.

[30]  T. Marwick,et al.  Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. , 2011, Journal of the American College of Cardiology.

[31]  R. Vasan,et al.  Epidemiology and clinical course of heart failure with preserved ejection fraction , 2011, European journal of heart failure.

[32]  J. Bronzwaer,et al.  Hypophosphorylation of the Stiff N2B Titin Isoform Raises Cardiomyocyte Resting Tension in Failing Human Myocardium , 2009, Circulation research.

[33]  Sanjiv J Shah,et al.  Heart failure with preserved ejection fraction: treat now by treating comorbidities. , 2008, JAMA.

[34]  Nancy M Albert,et al.  Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. , 2007, Journal of the American College of Cardiology.

[35]  Peter C Austin,et al.  Outcome of heart failure with preserved ejection fraction in a population-based study. , 2006, The New England journal of medicine.

[36]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[37]  D. Abrahamson,et al.  Loss of α3/α4(IV) Collagen from the Glomerular Basement Membrane Induces a Strain-Dependent Isoform Switch to α5α6(IV) Collagen Associated with Longer Renal Survival in Col4a3−/− Alport Mice , 2006 .

[38]  C. Yancy,et al.  Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. , 2006, Journal of the American College of Cardiology.

[39]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[40]  E. Fleck,et al.  Increased myocardial expression of osteopontin in patients with advanced heart failure , 2002, European journal of heart failure.

[41]  C. H. Conrad,et al.  Myocardial osteopontin expression coincides with the development of heart failure. , 1999, Hypertension.

[42]  E. Fleck,et al.  Myocardial osteopontin expression is associated with left ventricular hypertrophy. , 1997, Circulation.